The 'Buy' rating maintained by HC Wainwright & Co. indicates a positive outlook for Tempest Therapeutics. The increase in price target from $35 to $47 suggests that the analyst sees significant upside potential in the stock, which could lead to a positive short-term impact on the stock price.